|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
The American Cancer Society estimates
that colorectal cancer will be diagnosed in 147,000 Americans in 2003 and
will cause 57,100 deaths, making it the second-leading cancer killer. A seven-year randomized, double-blind
study lead by Overall, study participants treated with
a daily dose of baby aspirin found their risk of polyps reduced 19% and their
risk of advanced lesions reduced by more than 40%. Another study, conducted
among patients with a history of cancer of the colon or rectum, tested with a
regular 325mg aspirin tablet against placebo, showed a 35% reduction in the
occurrence of adenoma. This research provides support for the
emerging theory that non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, may reduce
a variety of malignancies. Although
there is evidence that inflammation plays a role in many cancers, the
strongest support for the beneficial effects of NSAIDs has been for
colorectal cancer. Previous non-randomized studies have found that people who
were taking aspirin for a variety of reasons, such as to reduce the risk of
heart disease or alleviate arthritis pain, were less likely to develop colon
cancer. This technology
is claimed in the Issued United States Patent No. 7,691,833. We are seeking an industrial partner
interested in its commercialization. (Ref: J188) |
||
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
|||
|
|
||||
|
11 Rope Ferry Road #6210 |
||||
|
Hanover, NH 03755-1404 |
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|